Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø-TB

Home
Menu

PanACEA

Pan African Consortium for the Evaluation of Antituberculosis Antibiotics

panacea

The consortium brings together a group of scientists from more than 14 countries with skills in clinical trials design and implementation, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service. At Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø the team includes Professor Tim McHugh, director of the Centre for Clinical Microbiology, and Dr Patrick Phillips and Ms Sunita Rehal at the MRC-Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Clinical Trials Unit.

PanACEA's mission is:

  • To shorten and simplify treatment of uncomplicated pulmonary TB
  • To increase the TB clinical trial capacity in Africa
  • To develop sustainable TB clinical trials network in Africa

At the annual Conference on Retroviruses and Opportunistic Infections (CROI), PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics, presented the results of its most recent phase IIb study (MAMS-TB-01). The most exciting finding from the study is that high-dose rifampicin results in faster killing of TB bacilli during treatment, compared to the current standard treatment. You can read more about this exciting development here.

Links